|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gridelli C, Rossi A, Carbone DP, Guarize
J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R:
Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
D'Addario G, Früh M, Reck M, Baumann P,
Klepetko W and Felip E: ESMO Guidelines Working Group: Metastatic
non-small-cell lung cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 21 Suppl
5:v116–v119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giovannetti E, Toffalorio F, De PT and
Peters GJ: Pharmacogenetics of conventional chemotherapy in
non-small-cell lung cancer: A changing landscape? Pharmacogenomics.
13:1073–1086. 2015. View Article : Google Scholar
|
|
5
|
Fatica A and Bozzoni I: Long non-coding
RNAs: New players in cell differentiation and development. Nat Rev
Genet. 15:7–21. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Engreitz JM, Ollikainen N and Guttman M:
Long non-coding RNAs: Spatial amplifiers that control nuclear
structure and gene expression. Nat Rev Mol Cell Biol. 17:756–770.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Quinn JJ and Chang HY: Unique features of
long non-coding RNA biogenesis and function. Nat Rev Genet.
17:47–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qi P and Du X: The long non-coding RNAs, a
new cancer diagnostic and therapeutic gold mine. Mod Pathol.
26:155–165. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang G, Li Z, Zhao Q, Zhu Y, Zhao C, Li X,
Ma Z, Li X and Zhang Y: LincRNA-p21 enhances the sensitivity of
radiotherapy for human colorectal cancer by targeting the
Wnt/β-catenin signaling pathway. Oncol Rep. 31:1839–1845. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia M, Jiang L, Wang YD, Huang JZ, Yu M
and Xue HZ: LincRNA-p21 inhibits invasion and metastasis of
hepatocellular carcinoma through Notch signaling-induced
epithelial-mesenchymal transition. Hepatol Res. 46:1137–1144. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ding G, Peng Z, Shang J, Kang Y, Ning H
and Mao C: LincRNA-p21 inhibits invasion and metastasis of
hepatocellular carcinoma through miR-9/E-cadherin cascade signaling
pathway molecular mechanism. OncoTargets Ther. 10:3241–3247. 2017.
View Article : Google Scholar
|
|
12
|
Castellano JJ, Navarro A, Viñolas N,
Marrades RM, Moises J, Cordeiro A, Saco A, Muñoz C, Fuster D,
Molins L, et al: LincRNA-p21 impacts prognosis in resected
non-small cell lung cancer patients through angiogenesis
regulation. J Thorac Oncol. 11:2173–2182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang C, Li Y, Li YW, Zhang HB, Gong H,
Yuan Y, Li WT, Liu HY and Chen J: HOTAIR lncRNA SNPs rs920778 and
rs1899663 are associated with smoking, male gender, and squamous
cell carcinoma in a Chinese lung cancer population. Acta Pharmacol
Sin. Aug 28–2018.(Epub ahead of print): View Article : Google Scholar
|
|
14
|
Fang L, Wu S, Zhu X, Cai J, Wu J, He Z,
Liu L, Zeng M, Song E, Li J, et al: MYEOV functions as an amplified
competing endogenous RNA in promoting metastasis by activating
TGF-β pathway in NSCLC. Oncogene. Sep 4–2018.(Epub ahead of
print) View Article : Google Scholar
|
|
15
|
Matsukuma S, Kono T, Takeo H, Hamakawa Y
and Sato K: Tumor-to-tumor metastasis from lung cancer: A
clinicopathological postmortem study. Virchows Arch. 463:525–534.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei L, Wu T, He P, Zhang JL and Wu W:
LncRNA ATB promotes the proliferation and metastasis of lung cancer
via activation of the p38 signaling pathway. Oncol Lett.
16:3907–3912. 2018.PubMed/NCBI
|
|
17
|
Qi L, Liu F, Zhang F, Zhang S, Lv L, Bi Y
and Yu Y: lncRNA NEAT1 competes against let-7a to contribute to
non-small cell lung cancer proliferation and metastasis. Biomed
Pharmacother. 103:1507–1515. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liao Y, Cheng S, Xiang J and Luo C: lncRNA
CCHE1 increased proliferation, metastasis and invasion of non-small
lung cancer cells and predicted poor survival in non-small lung
cancer patients. Eur Rev Med Pharmacol Sci. 22:1686–1692.
2018.PubMed/NCBI
|
|
19
|
Zhou WQ, Wang P, Shao QP and Wang J:
Lipopolysaccharide promotes pulmonary fibrosis in acute respiratory
distress syndrome (ARDS) via lincRNA-p21 induced inhibition of
Thy-1 expression. Mol Cell Biochem. 419:19–28. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tu X, Zhang Y, Zheng X, Deng J, Li H, Kang
Z, Cao Z, Huang Z, Ding Z, Dong L, et al: TGF-β-induced hepatocyte
lincRNA-p21 contributes to liver fibrosis in mice. Sci Rep.
7:29572017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng J, Dong P, Mao Y, Chen S, Wu X, Li
G, Lu Z and Yu F: lincRNA-p21 inhibits hepatic stellate cell
activation and liver fibrogenesis via p21. FEBS J. 282:4810–4821.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang F, Zhang H, Mei Y and Wu M:
Reciprocal regulation of HIF-1α and lincRNA-p21 modulates the
Warburg effect. Mol Cell. 53:88–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu G, Cai J, Han Y, Chen J, Huang ZP, Chen
C, Cai Y, Huang H, Yang Y, Liu Y, et al: lincRNA-p21 regulates
neointima formation, vascular smooth muscle cell proliferation,
apoptosis and atherosclerosis by enhancing p53 activity.
Circulation. 130:1452–1465. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hall J, Messenger ZJ, Tam HW, Phillips SL,
Recio L and Smart RC: Long non-coding RNA lincRNA-p21 is the major
mediator of UVB-induced and p53-dependent apoptosis in
keratinocytes. Cell Death Dis. 6:e17002016. View Article : Google Scholar
|
|
25
|
Bao X, Wu H, Zhu X, Guo X, Hutchins AP,
Luo Z, Song H, Chen Y, Lai K, Yin M, et al: The p53-induced
lincRNA-p21 derails somatic cell reprogramming by sustaining
H3K9me3 and CpG methylation at pluripotency gene promoters. Cell
Res. 25:80–92. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Lei ZJ, Guo Y, Wang T, Qin ZY,
Xiao HL, Fan LL, Chen DF, Bian XW, Liu J and Wang B:
miRNA-regulated delivery of lincRNA-p21 suppresses β-catenin
signaling and tumorigenicity of colorectal cancer stem cells.
Oncotarget. 6:37852–37870. 2015.PubMed/NCBI
|
|
27
|
Yu F, Guo Y, Chen B, Shi L, Dong P, Zhou M
and Zheng J: LincRNA-p21 inhibits the Wnt/β-catenin pathway in
activated hepatic stellate cells via sponging MicroRNA-17-5p. Cell
Physiol Biochem. 41:1970–1980. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang G, An X and Zhao H, Zhang Q and Zhao
H: Long non-coding RNA HNF1A-AS1 promotes cell proliferation and
invasion via regulating miR-17-5p in non-small cell lung cancer.
Biomed Pharmacother. 98:594–599. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chatterjee A, Chattopadhyay D and
Chakrabarti G: miR-17-5p downregulation contributes to paclitaxel
resistance of lung cancer cells through altering beclin1
expression. PLoS One. 9:e957162014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang W, Lin J, Wang P and Sun J:
miR-17-5p down-regulation contributes to erlotinib resistance in
non-small cell lung cancer cells. J Drug Target. 25:125–131. 2017.
View Article : Google Scholar : PubMed/NCBI
|
